Is Bayer (XTRA:BAYN) Undervalued On REVEAL Trial Success Or Is That Priced In?

How Bayer’s REVEAL data intersects with recent stock performance

Bayer (XTRA:BAYN) is in focus after the Phase III REVEAL study of iodine 124 evuzamitide for diagnosing cardiac amyloidosis met its primary endpoints on sensitivity and specificity, with data shared at a leading cardiology congress.

For shareholders, the news arrives after a strong run in the stock. Bayer shares closed at €49.04 on 29 August 2026, with total return over the past month at 2.1% and over the past 3 months at 43.8%.

Over the past year the stock delivered a 76.5% total return, while the 3 year total return is slightly negative at 2%. Over 5 years, the total return is 11.8%. These figures give you useful context when weighing how fresh data on an investigational radiotracer might influence sentiment around Bayer’s broader pharmaceuticals pipeline.

Bayer reports annual revenue of €45.4b and a reported net loss of €1.7b. That combination of sizeable top line and a loss making bottom line can lead investors to pay close attention to pipeline updates such as iodine 124 evuzamitide and other late stage assets when they think about the risk profile of the stock.

Bayer’s recent REVEAL data lands after a sharp 90 day share price return of 43.8% and a 1 year total shareholder return of 76.5%, which suggests momentum has been building as investors react to clinical updates and product approvals such as Hyrnuo in Japan.

Spot emerging pharma pipelines moving on fresh trial data by scanning our hand picked 613 high quality undiscovered gems alongside Bayer’s recent REVEAL and Hyrnuo updates.

After a 43.8% 90 day surge and with Bayer still reporting a net loss, the stock now poses a harder question: Does the current price fairly reflect the risk around the pipeline and crop science exposure, or not yet?

Most Popular Narrative: 13.7% Undervalued

Bayer’s most followed narrative points to a fair value of about €56.83 per share, compared with the recent close at €49.04, which sets up a clear valuation gap for investors to interrogate.

Sustained advances in Bayer's pharmaceutical innovation pipeline, evidenced by robust uptake in recently launched drugs and promising late-stage assets (such as asundexian and new indications for existing blockbusters), are positioned to offset patent expirations and generic erosion, supporting both revenue replacement and setting a path for higher margins in later years as these assets scale.

Read the complete narrative.

Want to see what underpins that higher fair value for Bayer? The narrative leans on steady revenue expansion, a sharp margin shift and a richer earnings profile. Curious which forecasts carry the most weight.

Result: Fair Value of €56.83 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the picture can shift quickly if glyphosate and PCB litigation costs rise above current provisions, or if key pharma assets underperform compared with analyst expectations.

Find out about the key risks to this Bayer narrative.

Next Steps

If this Bayer story feels encouraging, now is the time to pressure test it against your own research and judgement. Start by weighing the potential rewards that investors are focused on through the 3 key rewards.

Looking for more investment ideas beyond Bayer?

If Bayer has you thinking more broadly about opportunities, do not stop here. A wider watchlist can help you spot potential winners before they become crowded trades.

• Spot potential mispricings early and compare them with Bayer by scanning a focused list of 262 high quality undervalued stocks that may warrant a closer look.
• Strengthen your core holdings with companies that prioritise resilience and prudent finances by checking the list of solid balance sheet and fundamentals (433 results).
• Get ahead of the crowd by tracking under followed opportunities through the 613 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com